Edge
StocktwitsEarnings

Official STOCKTWITS Representative

$RPRX Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.03 down -57.14% YoY
• Reported revenue of $674M up 16.47% YoY
• Royalty Pharma raised its full year 2026 guidance for Portfolio Receipts to between $3,400 million and $3,500 million, representing expected Royalty Receipts growth of 7% to 10% for Royalty Pharma.Price since post
Advertisement|Remove ads.